Vascular antithrombin and clinical outcome in heart transplant patients
| Autor: | Douglas E. Pitts, Steven J. Miller, Philip C. Kirlin, Carlos A. Labarrere, Harold Halbrook, Ronald J. Torry, David R. Nelson |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Graft Rejection
medicine.medical_specialty Biopsy Coronary Disease Coronary Angiography Antithrombins Statistics Nonparametric Pathogenesis Coronary artery disease Internal medicine Humans Medicine Prospective Studies cardiovascular diseases Proportional Hazards Models medicine.diagnostic_test business.industry Vascular disease Myocardium Antithrombin medicine.disease Immunohistochemistry Survival Analysis Pathophysiology Transplantation Logistic Models Treatment Outcome Cardiology Heart Transplantation Cardiology and Cardiovascular Medicine business Complication medicine.drug |
| Zdroj: | The American Journal of Cardiology. 87:425-431 |
| ISSN: | 0002-9149 |
| DOI: | 10.1016/s0002-9149(00)01395-3 |
| Popis: | A procoagulant microvasculature is associated with accelerated development of coronary artery disease (CAD) and failure in heart transplant patients. This study was performed to evaluate how changes in natural anticoagulation within cardiac allografts affect outcome. We prospectively studied 141 consecutive cardiac allograft recipients who underwent transplantation between 1988 and 1997. Serial endomyocardial biopsy specimens (6.5 ± 0.1 biopsy specimens/patient) obtained during the first 3 months after transplantation were studied immunohistochemically to evaluate vascular antithrombin, and annual coronary angiograms (3.8 ± 0.2 angiograms/patient) were studied to evaluate CAD. Antithrombin was present in arteries and veins, but not in capillaries, of all donor heart biopsy samples. Allografts that maintained vascular antithrombin had the best prognosis. Allografts with early and persistent loss of vascular antithrombin (n = 21) developed CAD earlier (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect